top of page

Search Results

Search this site

658 results found with an empty search

  • Teva acquires BioXcel neuroscience assets including BXCL501 for up to $125 million

    Teva has acquired worldwide rights to BioXcel's BXCL501 neuroscience programme and approved IGALMI product in an asset transaction worth up to $125 million. The completed acquisition transfers specified BioXcel Therapeutics assets to Teva, including investigational BXCL501 dexmedetomidine sublingual film and the FDA-approved hospital-use product IGALMI, following a US bankruptcy court-supervised sale. Teva will pay $57.5 million upfront and may make up to $67.5 million in additional regulatory and sales-related payments, while BXCL501 remains under FDA review for potential at-home treatment of acute agitation associated with schizophrenia or bipolar disorder in adults. Field Content Article Type Deals Acquirer Teva Pharmaceutical Industries Asset Seller BioXcel Therapeutics Deal Type Acquisition of specified pharmaceutical assets and worldwide rights Transaction Status Completed Announcement Date 27 October 2026 Transaction Process US bankruptcy court-supervised asset sale Acquired Development Asset BXCL501 Acquired Approved Product IGALMI Active Ingredient Dexmedetomidine Drug Formulation Sublingual film Therapeutic Area Neuroscience; psychiatry Investigational Indication At-home treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults Existing Approved Use IGALMI for hospital-use treatment of acute agitation in its approved patient population BXCL501 Regulatory Status Under FDA review for proposed at-home use; not approved for that use in supplied summary Acquired Rights Worldwide rights to specified assets Upfront Payment $57.5 million Contingent Payments Up to $67.5 million Maximum Transaction Value Up to $125 million Contingent Payment Triggers Regulatory and sales-related milestones Company Acquisition Status Teva acquired specified assets, not BioXcel Therapeutics as a company What Happened Teva completed an acquisition of BioXcel neuroscience assets following a bankruptcy court-supervised sale. Why It Matters The transaction strengthens Teva's neuroscience portfolio with an approved agitation treatment and a related investigational at-home treatment opportunity. Strategic Rationale Expand Teva's innovative neuroscience pipeline and potential treatment options for acute agitation. Key Takeaway Teva secured worldwide rights to BXCL501 and IGALMI for $57.5 million upfront plus up to $67.5 million in contingent payments. What to Watch FDA review of the proposed at-home indication, regulatory decisions, product integration, commercial development and milestone achievement. Primary Source Teva Pharmaceutical Industries Primary Source URL https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Acquires-Worldwide-Rights-to-BXCL501-Further-Expanding-Innovative-Neuroscience-Pipeline/default.aspx Relevant Date 27 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Corxel agrees $377 million SPAC combination with Amanat to fund oral obesity drug development

    Corxel Pharmaceuticals US has agreed to merge with Amanat Acquisition Corp in a SPAC transaction expected to provide approximately $377 million in gross proceeds for its oral obesity drug pipeline. The proposed business combination includes a committed approximately $300 million private investment in public equity and is intended to finance Phase III development of CX11, an investigational oral small-molecule GLP-1 receptor agonist for obesity. Assuming no shareholder redemptions, the transaction is expected to support operations through 2029, with completion anticipated in the first half of 2027 subject to shareholder approvals and other closing conditions. Field Content Article Type Deals Companies Corxel Pharmaceuticals US; Amanat Acquisition Corp Deal Type Definitive SPAC business combination agreement Transaction Status Announced; not yet completed Announcement Date 26 October 2026 Target Company Corxel Pharmaceuticals US SPAC Partner Amanat Acquisition Corp Expected Gross Proceeds Approximately $377 million assuming no shareholder redemptions Committed PIPE Financing Approximately $300 million PIPE Meaning Private investment in public equity Transaction Valuation Not confirmed in supplied summary Acquisition Consideration Not specified; expected gross proceeds are not acquisition consideration Lead Development Asset CX11 Therapeutic Modality Oral small-molecule GLP-1 receptor agonist Therapeutic Area Metabolic disease; obesity Target Indication Obesity Planned Development Phase III clinical development Expected Operating Runway Through 2029 Expected Transaction Closing First half of 2027 Closing Conditions Subject to shareholder approvals and other customary closing conditions What Happened Corxel Pharmaceuticals US and Amanat Acquisition Corp announced a definitive agreement for a proposed SPAC business combination. Why It Matters The transaction could provide substantial capital to advance an oral GLP-1 obesity treatment through late-stage clinical development. Strategic Rationale Access public-market capital to fund CX11 development and establish a publicly listed obesity-focused biopharmaceutical company. Financial Structure Approximately $377 million in expected gross proceeds includes a committed approximately $300 million PIPE; proceeds depend on transaction assumptions. Key Takeaway The proposed merger could finance Corxel's obesity pipeline into 2029, but completion and the full expected proceeds remain conditional. What to Watch Shareholder approvals, redemption levels, transaction closing, final financing proceeds and CX11 Phase III initiation. Primary Source Corxel Pharmaceuticals US and Amanat Acquisition Corp via GlobeNewswire Primary Source URL https://www.globenewswire.com/news-release/2026/10/26/3387902/0/en/corxel-us-and-amanat-acquisition-corp-announce-definitive-business-combination-agreement-to-create-publicly-listed-obesity-focused-biopharmaceutical-company.html Relevant Date 26 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves at-home subcutaneous Skyrizi induction for adults with Crohn's disease

    The FDA has approved an at-home subcutaneous induction regimen for AbbVie's Skyrizi in Crohn's disease, offering an alternative to intravenous treatment initiation. Adults with moderately to severely active Crohn's disease can now begin Skyrizi (risankizumab-rzaa) treatment through an approved subcutaneous induction regimen using an on-body injector, rather than relying exclusively on intravenous induction. The Phase III AFFIRM study demonstrated superior clinical remission and endoscopic response at week 12 versus placebo, supporting the additional administration option for eligible patients. Field Content Article Type Approvals Regulatory Authority U.S. Food and Drug Administration Regulatory Decision Approval of an additional administration regimen Announcement Date 23 October 2026 Company AbbVie Drug Name Skyrizi Generic Name Risankizumab-rzaa Therapeutic Area Gastroenterology; inflammatory bowel disease Approved Indication Moderately to severely active Crohn's disease in adults New Administration Option Subcutaneous induction Delivery Device On-body injector Treatment Location At-home induction for eligible patients Previous Induction Route Intravenous infusion Supporting Clinical Study Phase III AFFIRM Clinical Endpoints Clinical remission and endoscopic response at week 12 Reported Study Outcome Superior clinical remission and endoscopic response versus placebo Numerical Efficacy Results Not provided in supplied summary Geography United States What Happened The FDA approved a subcutaneous induction regimen for Skyrizi in adults with moderately to severely active Crohn's disease. Why It Matters The new administration option may reduce dependence on infusion-centre visits during treatment initiation and improve convenience for eligible patients. Clinical Evidence AFFIRM demonstrated superior clinical remission and endoscopic response at week 12 compared with placebo. Key Takeaway Skyrizi now offers an FDA-approved at-home subcutaneous induction option for Crohn's disease, distinct from its established intravenous induction regimen. What to Watch Prescribing information, payer coverage, device training, patient uptake, adherence and real-world treatment outcomes. Primary Source AbbVie via PR Newswire Primary Source URL https://www.prnewswire.com/news-releases/us-fda-approves-subcutaneous-induction-regimen-for-abbvies-skyrizi-risankizumab-rzaa-for-adults-with-moderately-to-severely-active-crohns-disease-302918434.html Relevant Date 23 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • China approves Bio-Thera BAT2306 as world's first secukinumab biosimilar

    China has approved Bio-Thera's BAT2306 as the first secukinumab biosimilar authorised by a major regulator worldwide, opening a new biosimilar competition category. Bio-Thera's BAT2306, marketed as YOUZHUOMEI, has received approval from China's National Medical Products Administration as a biosimilar to secukinumab for psoriasis, ankylosing spondylitis and psoriatic arthritis. The company identifies the decision as the first major-regulator approval of a secukinumab biosimilar, creating a new potential treatment alternative across three immune-mediated inflammatory conditions. Field Content Article Type Approvals Regulatory Authority China National Medical Products Administration Regulatory Decision Biosimilar marketing approval Company Bio-Thera Solutions Product Development Code BAT2306 Brand Name YOUZHUOMEI Reference Medicine Secukinumab Product Type Biosimilar monoclonal antibody Therapeutic Area Immunology; inflammatory diseases Approved Indications Psoriasis; ankylosing spondylitis; psoriatic arthritis Approval Geography China Regulatory Significance Reported by Bio-Thera as the first secukinumab biosimilar approved by a major regulator worldwide Approval Announcement Date 22 October 2026 English Announcement Date 26 October 2026 Clinical Evidence Specific comparative clinical study results not provided in supplied summary Commercial Launch Timing Not confirmed in supplied summary Pricing Not disclosed What Happened China's NMPA approved Bio-Thera's BAT2306 as a secukinumab biosimilar for three inflammatory conditions. Why It Matters The approval introduces a biosimilar competitor to secukinumab and could support broader treatment access and price competition in China. Market Significance Bio-Thera describes BAT2306 as the world's first secukinumab biosimilar authorised by a major regulatory authority. Key Takeaway BAT2306 has obtained Chinese marketing approval for psoriasis, ankylosing spondylitis and psoriatic arthritis; international authorisations are not established by this decision. What to Watch Commercial launch, pricing, reimbursement, physician uptake, supply availability and regulatory filings in other markets. Primary Source Bio-Thera Solutions Primary Source URL https://www.bio-thera.com/news/1001462.html Relevant Date 22 October 2026; English announcement 26 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves Talzenna plus Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer

    The FDA has approved Pfizer's Talzenna plus Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer, expanding the combination into an earlier treatment setting. The approval authorises Talzenna (talazoparib) with Xtandi (enzalutamide) for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer whose tumours harbour homologous recombination repair gene mutations identified using an FDA-authorised test. The decision was supported by the Phase III TALAPRO-3 study involving 599 patients and extends the combination's use beyond its previously authorised metastatic castration-resistant prostate cancer indication. Field Content Article Type Approvals Regulatory Authority U.S. Food and Drug Administration Regulatory Decision New indication approval Approval Date 26 October 2026 Company Pfizer Approved Combination Talzenna plus Xtandi Active Ingredients Talazoparib; enzalutamide Drug Classes PARP inhibitor; androgen receptor inhibitor Therapeutic Area Oncology; prostate cancer Approved Indication Metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations Patient Population Adults with eligible HRR-mutated metastatic prostate cancer Biomarker Homologous recombination repair gene mutations Biomarker Testing FDA-authorised test Supporting Clinical Study Phase III TALAPRO-3 Study Enrollment 599 patients Efficacy Results Specific efficacy estimates not provided in supplied summary Previous Approved Setting Metastatic castration-resistant prostate cancer New Treatment Setting Earlier metastatic androgen pathway modulation-naïve or -sensitive disease Geography United States What Happened The FDA approved talazoparib with enzalutamide for adults with HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. Why It Matters The approval expands access to a biomarker-directed PARP inhibitor combination earlier in the metastatic prostate cancer treatment pathway. Clinical Evidence The Phase III TALAPRO-3 study enrolled 599 patients; detailed efficacy outcomes were not included in the supplied summary. Key Takeaway Talzenna plus Xtandi now has an additional US indication for selected HRR-mutated metastatic prostate cancers beyond the castration-resistant setting. What to Watch Updated prescribing information, biomarker testing uptake, clinical guideline integration, reimbursement and real-world outcomes. Primary Source U.S. Food and Drug Administration Primary Source URL https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive Relevant Date 26 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Biocon expands Yesintek biosimilar licensing rights to nine additional international markets

    Biocon has secured additional licensing rights for its Yesintek ustekinumab biosimilar across nine international markets, broadening its planned commercial footprint. The agreement with Janssen Sciences Ireland covers Yesintek, a proposed biosimilar to Stelara, in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan. The new rights extend Biocon's previously established market-entry arrangements, although financial terms were not disclosed and commercial launches remain dependent on applicable national regulatory approvals. Field Content Article Type Deals Companies Biocon; Janssen Sciences Ireland Deal Type International biosimilar licensing and market-entry agreement Licensee Biocon Licensing Counterparty Janssen Sciences Ireland Product Yesintek Active Ingredient Ustekinumab Reference Medicine Stelara Product Category Proposed biosimilar Therapeutic Area Immunology; immune-mediated inflammatory diseases Newly Covered Markets Australia; Brazil; China; Hong Kong; Israel; Mexico; New Zealand; South Korea; Kazakhstan Number of Additional Markets 9 Existing Market Context Previously secured market-entry rights in the United States and other major regions Financial Terms Not disclosed Upfront Payment Not disclosed Milestone Payments Not disclosed Royalties Not disclosed Regulatory Status Country-specific regulatory approvals remain necessary where applicable Commercial Launch Timing Not confirmed in supplied summary Announcement Date 26 October 2026 What Happened Biocon entered an agreement with Janssen Sciences Ireland expanding Yesintek market-entry rights to nine additional international territories. Why It Matters The agreement increases the potential geographic reach of Biocon's ustekinumab biosimilar and could support future biosimilar competition in additional markets. Strategic Rationale Expand Biocon's international biosimilar commercialisation opportunities through additional licensed territories. Regulatory Distinction The announcement concerns licensing and market-entry rights, not nine new marketing authorisations. Key Takeaway Biocon has secured Yesintek rights across nine additional markets, with actual commercialisation subject to national regulatory requirements. What to Watch Country-specific approvals, launch schedules, pricing, reimbursement decisions, supply arrangements and market uptake. Primary Source Biocon Primary Source URL https://www.biocon.com/biocon-secures-market-entry-for-yesintek-a-proposed-biosimilar-to-stelara-in-additional-global-markets/ Relevant Date 26 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • European Commission approves Tecvayli monotherapy from first relapse in multiple myeloma

    The European Commission has approved Johnson & Johnson's Tecvayli monotherapy from first relapse in multiple myeloma, moving the bispecific antibody into an earlier treatment setting. Tecvayli (teclistamab) is now authorised in the European Union as monotherapy for adults with relapsed or refractory multiple myeloma after at least one prior therapy, expanding its use beyond later-line treatment. In the Phase III MajesTEC-9 study, teclistamab reduced the risk of disease progression or death by 71% and the risk of death by 40% compared with standard-of-care regimens, supporting its use from the second-line setting. Field Content Article Type Approvals Regulatory Authority European Commission Regulatory Decision Marketing authorisation indication extension Announcement Date 23 October 2026 Company Johnson & Johnson Drug Name Tecvayli Generic Name Teclistamab Therapeutic Modality Bispecific antibody Therapeutic Area Haematology; oncology Approved Indication Monotherapy for adults with relapsed or refractory multiple myeloma after at least one prior therapy Patient Population Adults with relapsed or refractory multiple myeloma Minimum Prior Treatment At least one prior therapy Treatment Setting From first relapse; second-line and later Treatment Regimen Tecvayli monotherapy Supporting Clinical Study Phase III MajesTEC-9 Comparator Standard-of-care regimens Progression or Death Risk Reduction 71% relative risk reduction Death Risk Reduction 40% relative risk reduction Geography European Union Previous Regulatory Context Tecvayli was previously authorised in later-line multiple myeloma settings; this monotherapy extension is distinct from the Tecvayli plus daratumumab approval What Happened The European Commission expanded Tecvayli's monotherapy indication to adults with relapsed or refractory multiple myeloma after at least one prior treatment. Why It Matters The decision makes a bispecific antibody treatment option available earlier in the European multiple myeloma care pathway. Clinical Evidence MajesTEC-9 reported a 71% reduction in progression or death risk and a 40% reduction in death risk versus standard-of-care regimens. Key Takeaway Tecvayli monotherapy can now be used from first relapse in eligible EU patients, supported by Phase III evidence. What to Watch European reimbursement decisions, treatment sequencing, specialist centre adoption, safety management and long-term outcomes. Primary Source Johnson & Johnson Innovative Medicine Primary Source URL https://www.jnj.com/innovativemedicine/emea/media-center/press-releases/european-commission-approves-johnson-johnsons-tecvayli-teclistamab-monotherapy-for-relapsed-refractory-multiple-myeloma-expanding-treatment-options-from-first-relapse Relevant Date 23 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • nuaxia launches verified global database of 6.4 million profiled healthcare professionals

    New global resource combines HCP reach with independently sourced specialty and specialism intelligence nuaxia has announced the development of a global database of more than 6.4 million contactable healthcare professionals across 249 countries and territories. Every HCP is profiled with core professional information including country of practice and specialty, together with detailed clinical specialisms where these can be established. Unlike traditional approaches that rely heavily on self-declared information, nuaxia builds its professional profiles from independent and authoritative sources. Peter Chopra, Founder and CEO of nuaxia, said: “Knowing somebody is a genuine doctor is not enough. You also need good evidence that they are the right doctor for the question you are asking. “Research recruitment still relies heavily on asking people to declare that they meet the criteria required to participate. But asking a question does not make the answer true. “That matters because the consequences can be significant. Independent testing by NewtonX has shown differences of 20–30% between results from verified and unverified professional samples, while the wider research industry continues to report substantial levels of fraudulent and poor-quality participation. “Our approach is to do more of the work before the HCP is ever contacted: identify the people who appear relevant from independently sourced professional evidence, rather than repeatedly asking them to prove who they are and what they do.” The approach is intended both to strengthen audience selection and improve the experience of healthcare professionals participating in research. “Doctors are not simply units of sample,” Chopra added. “They are the pharmaceutical industry’s customers, partners and clinical stakeholders. Better data should allow us to treat their time with considerably more respect.” The database also links HCPs to approximately 2.1 million healthcare organisations globally and provides the data foundation for nuaxia’s wider healthcare intelligence capabilities. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Advancing Immunology Learning: Evidence-Based Insights for Healthcare

    Exploring evidence-based approaches to immunology education and their effectiveness in knowledge retention. Immunology underpins many of today’s most significant therapeutic advances, from biologics to personalised medicine. As the field evolves, the effectiveness of immunology education becomes increasingly important. nuaxia conducted a detailed analysis of behavioural data from immunology education activities to assess how learning interventions shape professional competence. By examining pre- and post-education performance, nuaxia’s analysis delivers objective insights into how immunology education influences knowledge retention and clinical understanding, offering a clearer view of educational impact in this rapidly advancing discipline. Key Findings at a Glance 93% of Participants Improved Their Scores Nearly all participants achieved improvements in knowledge and competence, underscoring the tangible benefits of our CME initiatives. 69% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 69% improved 29% remained stable Only 2% saw a decrease This shows that structured medical education adapts to HCPs’ starting points while driving measurable development. 41% Achieved the Top Score After Medical Education Activity Notably, 41% of participants reached the top performance group, showing that CME activities are helping a significant portion of HCPs achieve high performance. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (49.0%) or Average (36.7%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (45.8%) or Top (41.4%) categories. This shows that well-designed medical education can transform professional performance, not just understanding. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change Not only do HCPs gain from this education, but patients also experience improved outcomes globally. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Bolt Biotherapeutics acquires Prana Therapies alongside $120 million financing to advance inflammatory disease pipeline

    Bolt Biotherapeutics has acquired Prana Therapies in a stock-for-stock transaction and arranged $120 million in financing to advance a new inflammatory disease pipeline. The acquisition adds Prana Therapies' INSPIRE multispecific antibody platform and lead candidate PRA-216, an investigational IL-4Rα/TSLP bispecific antibody in Phase II development for asthma, COPD and atopic dermatitis. Bolt separately arranged a $120 million private placement with the potential for up to $60 million in additional warrant proceeds, providing funding intended to support operations into 2028; these financing amounts are separate from the acquisition consideration. Field Content Article Type Deals Acquirer Bolt Biotherapeutics Acquired Company Prana Therapies Deal Type Stock-for-stock acquisition structured as a reverse merger Transaction Status Completed Announcement Date 23 October 2026 Acquisition Consideration Stock-for-stock; monetary valuation not specified in supplied summary Acquired Technology Platform INSPIRE multispecific antibody platform Lead Acquired Asset PRA-216 Therapeutic Modality Bispecific antibody Molecular Targets IL-4Rα and TSLP Therapeutic Area Immunology and inflammatory diseases Target Indications Asthma; chronic obstructive pulmonary disease; atopic dermatitis Development Stage Phase II Separate Financing $120 million private placement Potential Additional Financing Up to $60 million from warrant exercises Total Potential Financing Up to $180 million including contingent warrant proceeds Financing Versus Acquisition Consideration The private placement and potential warrant proceeds are separate financing arrangements and are not acquisition consideration Expected Cash Runway Into 2028, according to the supplied transaction summary Financing Purpose Support clinical development and company operations Geography Not specified in supplied summary What Happened Bolt Biotherapeutics acquired Prana Therapies in a stock-for-stock transaction and separately arranged a $120 million private placement. Why It Matters The acquisition adds a Phase II inflammatory disease candidate and a multispecific antibody platform, repositioning Bolt's development pipeline. Strategic Rationale Combine Prana's investigational immunology assets with Bolt's corporate and development infrastructure, supported by new financing. Pipeline Impact PRA-216 provides exposure to asthma, COPD and atopic dermatitis development programmes. Financial Impact The $120 million private placement and up to $60 million in potential warrant proceeds are intended to extend the company's operating runway into 2028. Key Takeaway Bolt has acquired a clinical-stage inflammatory disease pipeline through a stock transaction, while securing separate financing to support its development strategy. What to Watch PRA-216 Phase II clinical results, subsequent development plans, regulatory interactions, warrant exercises and the company's operating cash runway. Primary Source Bolt Biotherapeutics Primary Source URL https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-announces-acquisition-prana-therapies-and Relevant Date 23 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA grants full approval to Keytruda and Keytruda Qlex for TMB-high advanced solid tumours with updated biomarker threshold

    The FDA has converted Keytruda's tumour-mutational-burden-high solid tumour indication to traditional approval, extending the authorisation to Keytruda Qlex and updating the biomarker threshold. Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) are authorised for previously treated adults and children with unresectable or metastatic TMB-high solid tumours, defined as at least 13 mutations per megabase using an FDA-authorised test, when satisfactory alternative treatments are unavailable. The decision replaces an earlier accelerated approval and raises the biomarker threshold from 10 to 13 mutations per megabase, supported by KEYNOTE-158 data showing a 36% objective response rate among 220 patients, with 58% of responders maintaining responses for at least 12 months. Field Content Article Type Approvals Regulatory Authority U.S. Food and Drug Administration Regulatory Decision Traditional approval replacing an earlier accelerated approval Approval Date 16 October 2026 Company Merck & Co. Approved Products Keytruda; Keytruda Qlex Keytruda Active Ingredient Pembrolizumab Keytruda Qlex Active Ingredients Pembrolizumab and berahyaluronidase alfa-pmph Therapeutic Area Oncology Approved Indication Previously treated unresectable or metastatic tumour-mutational-burden-high solid tumours without satisfactory alternative treatment options Patient Population Adults and children meeting the approved biomarker and prior-treatment criteria Biomarker Tumour mutational burden-high (TMB-H) Updated TMB Threshold At least 13 mutations per megabase Previous TMB Threshold At least 10 mutations per megabase Biomarker Testing FDA-authorised test Prior Treatment Requirement Previously treated disease Alternative Treatment Requirement No satisfactory alternative treatment options Supporting Clinical Study KEYNOTE-158 Study Population 220 patients in the reported efficacy analysis Objective Response Rate 36% Response Durability 58% of responders maintained responses for at least 12 months Threshold Change Rationale Efficacy was not confirmed in the subgroup with TMB of 10 to below 13 mutations per megabase Regulatory History Conversion of an earlier accelerated approval to traditional approval with a revised biomarker threshold Geography United States What Happened The FDA granted traditional approval to Keytruda and Keytruda Qlex for eligible patients with TMB-high unresectable or metastatic solid tumours. Why It Matters The decision confirms a biomarker-directed, tumour-agnostic treatment indication while refining the population based on observed efficacy. Clinical Evidence KEYNOTE-158 reported a 36% objective response rate in 220 patients and response duration of at least 12 months in 58% of responders. Key Takeaway Traditional approval now applies to Keytruda and Keytruda Qlex for eligible TMB-high advanced solid tumours using a threshold of at least 13 mutations per megabase. What to Watch Updated biomarker testing practices, clinical guideline revisions, treatment selection, real-world outcomes and adoption of the revised threshold. Primary Source U.S. Food and Drug Administration Primary Source URL https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph Relevant Date 16 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Menarini Stemline licenses Georgiamune GIM-621 oral cancer immunotherapy in deal worth up to $1.1 billion

    Menarini's Stemline Therapeutics has secured worldwide rights to Georgiamune's investigational oral cancer immunotherapy GIM-621 in a licensing agreement worth up to $1.1 billion. The exclusive collaboration gives Stemline global development, manufacturing and commercialisation rights to GIM-621, a preclinical first-in-class oral small-molecule immunotherapy being investigated for multiple solid tumours. Georgiamune will receive $45 million in combined upfront and near-term payments and may earn additional preclinical, development, regulatory and commercial milestones, bringing potential consideration to $1.1 billion plus royalties. Field Content Article Type Deals Companies Menarini Group; Stemline Therapeutics; Georgiamune Deal Type Exclusive worldwide licensing and collaboration agreement Licensor Georgiamune Licensee Stemline Therapeutics, a Menarini Group company Licensed Asset GIM-621 Therapeutic Area Oncology Target Indications Multiple solid tumours under investigation Therapeutic Modality Oral small-molecule immunotherapy Asset Description Investigational first-in-class oral immuno-oncology agent Development Stage Preclinical Licensed Rights Global development, manufacturing and commercialisation Territory Worldwide Upfront and Near-Term Payments $45 million combined; individual amounts not disclosed Total Potential Deal Value Up to $1.1 billion plus royalties Additional Milestones Preclinical, development, regulatory and commercial milestones; individual amounts not disclosed Royalties Additional royalties; rates not disclosed Announcement Date 22 October 2026 What Happened Menarini subsidiary Stemline Therapeutics entered an exclusive global licensing and collaboration agreement for Georgiamune's GIM-621. Why It Matters The transaction adds a novel investigational oral immunotherapy programme to Menarini's oncology pipeline and provides Georgiamune with funding and potential downstream payments. Strategic Rationale Stemline gains worldwide rights to advance GIM-621 while Georgiamune benefits from a pharmaceutical development and commercialisation partner. Key Takeaway The agreement carries up to $1.1 billion in potential consideration plus royalties, but GIM-621 remains preclinical and most payments depend on future milestones. What to Watch Preclinical validation, investigational new drug preparation, first-in-human development, target indications and milestone achievements. Primary Source Menarini Group Primary Source URL https://www.menarini.com/en-us/news/news-detail/georgiamune-and-menarini-group-enter-exclusive-global-license-and-collaboration-agreement-for-gim-621-a-first-in-class-oral-immuno-oncology-agent.html Relevant Date 22 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

bottom of page